This is a preprint.
Astrocyte-derived MFG-E8 facilitates microglial synapse elimination in Alzheimer's disease mouse models
- PMID: 39257734
- PMCID: PMC11383703
- DOI: 10.1101/2024.08.31.606944
Astrocyte-derived MFG-E8 facilitates microglial synapse elimination in Alzheimer's disease mouse models
Abstract
Region-specific synapse loss is an early pathological hallmark in Alzheimer's disease (AD). Emerging data in mice and humans highlight microglia, the brain-resident macrophages, as cellular mediators of synapse loss; however, the upstream modulators of microglia-synapse engulfment remain elusive. Here, we report a distinct subset of astrocytes, which are glial cells essential for maintaining synapse homeostasis, appearing in a region-specific manner with age and amyloidosis at onset of synapse loss. These astrocytes are distinguished by their peri-synaptic processes which are 'bulbous' in morphology, contain accumulated p62-immunoreactive bodies, and have reduced territorial domains, resulting in a decrease of astrocyte-synapse coverage. Using integrated in vitro and in vivo approaches, we show that astrocytes upregulate and secrete phagocytic modulator, milk fat globule-EGF factor 8 (MFG-E8), which is sufficient and necessary for promoting microglia-synapse engulfment in their local milieu. Finally, we show that knocking down Mfge8 specifically from astrocytes using a viral CRISPR-saCas9 system prevents microglia-synapse engulfment and ameliorates synapse loss in two independent amyloidosis mouse models of AD. Altogether, our findings highlight astrocyte-microglia crosstalk in determining synapse fate in amyloid models and nominate astrocytic MFGE8 as a potential target to ameliorate synapse loss during the earliest stages of AD.
Conflict of interest statement
SH has received speaking fees from Eisai Ltd, Novo Nordisk, and Alnylam; SH receives research funding from Eisai Ltd; SH has a collaborative project with Ionis Ltd. DS receives research funding from AstraZeneca. During this research, OJF was employed by AstraZeneca; OJF is now employed by MSD. All the other authors declare that they have no competing interests.
Figures





References
-
- DeKosky S. T. & Scheff S. W. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Ann Neurol 27, 457–464 (1990). - PubMed
-
- Scheff S. W., Price D. A., Schmitt F. A. & Mufson E. J. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 27, 1372–1384 (2006). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous